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To the Editors:
Wilson’s Disease (WD) is an inherited, multisystem dis-
order of copper metabolism in which pathological copper 
accumulation in different organs results in secondary damage 
of affected tissues (mainly the liver and brain) and symptoms 
related to affected systems (mainly hepatic and/or neuropsy-
chiatric) [1–2]. Notably, WD is one of the few genetic neuro-
degenerative disorders that can be successfully treated with 
pharmacological agents. The most important determinants of 
outcome are early diagnosis and treatment [1–2]. 
 The diagnosis of WD has been performed mostly by cop-
per metabolism assessment and genetic tests. Nowadays, an ad-
ditional algorithm including genetics, copper metabolism and 
clinical symptoms score (the Leipzig score) is used to improve 
WD diagnosis in doubtful cases (Tab. 1) [1]. However, despite 
the progress in WD diagnosis (genetic tests, algorithms), 
difficulties often occur, as highlighted in the following case.
We present the case of a 47-year-old female patient who 
had been suffering from idiopathic immunodeficiency syn-
drome for 19 years and was receiving monthly intravenous 
immunoglobulin administration. In addition, she was diag-
nosed, in gastroenterology departments, based on histologi-
cal and serological examinations (according to international 
guidelines) [3, 4], with coeliac disease (treated with gluten-free 
diet) and ulcerative colitis (treated with mesalazine). 
Three years ago, she began to experience hepatic symptoms 
including abdominal pain, increased weakness and weight loss. 
Liver enzymes were increased and she also had low serum 
albumin levels (2.03 g/dL; normal 3.5–5.0) and a high interna-
tional normalised ratio (1.78; normal 0.8–1.2), indicating the 
impairment of liver synthetic function. Ultrasound examination 
of the liver documented cirrhosis (no liver biopsy was performed 
due to coagulopathy). Triggers of cirrhosis, namely autoimmu-
nology illnesses, infectious diseases, and metabolic causes were 
excluded. The cause of liver injury remained unknown; however, 
WD was suspected and she was admitted to our department for 
further diagnosis. She was underweight (body mass index 13 kg/
m2), had enlarged abdominal circumference, ankle oedema and 
subcutaneous haemorrhage on the limbs.
She had no neurological signs characteristic of WD, with 
no tremor, ataxia, dystonia, or speech problems. Serum ceru-
loplasmin level was very low at 4.7 mg/dL (normal 25–45 mg/
dL) and total serum copper level was also very low at 14.7 µg/
dL (normal 70–140 µg/dL). Daily urinary copper excretion 
was normal at 9 µg/24 h (normal 0–50 µg/24 h). Her mother, 
aged 75, was alive and not suffering from liver, neurological 
or psychiatric symptoms. Her father was unknown and she 
had no siblings or children. Brain magnetic resonance imag-
ing (MRI) showed only discreetly hyperintense changes in 
T1-weighted images in the globus pallidus, which are changes 
that are atypical for WD, but are often seen in the course of 
liver failure, probably due to brain manganese accumulation 
(Fig. 1). A slit-lamp examination excluded the presence of 
Kayser-Fleischer (K-F) rings.
DNA analyses with Sanger’s sequencing method showed 
two variants classified as disease-causing variants in the Wilson 
Disease Mutation Database (http://www.wilsondisease.med.
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Figure 1. Brain magnetic resonance imaging (MRI). Hyperintense 
changes in T1-weighted images in the globus pallidus characteri-
stic of hepatic encephalopathy
Table 1. Scoring system (Leipzig score) for the diagnosis of Wilson’s Disease developed at the 8th International Meeting on Wilson’s Disease and Menkes 
Disease, Leipzig 2002 [1]
Clinical symptoms, sings and other tests Score
Kayser-Fleischer rings  Present (2 points) Absent (0 points)
Neuropsychiatric symptoms suggest WD (or 
typical brain MRI)
 Yes (2 points) No (0 points)
Coombs negative haemolytic anaemia Yes (1 point) No (0 points)
24-hour urinary copper excretion (in the absen-
ce of acute hepatitis)
 > 2 x ULN or normal but > 5 x ULN after 
challenge with 2 x 0.5 g D-penicillamine 
(2 points)
1–2 x ULN (1 point) Normal (0 points)
Quantitive liver copper assessment > 5 x ULN (2 points) < 5 x ULN (1 point) Normal (-1 point)
Rhodanine-positive hepatocytes (if no quantita-
tive liver copper assessment is available)
Present (1 point) Absent (0 points)
Serum ceruloplasmin (nephelometric assay, 
normal > 20 mg/dL)
< 10 mg/dL  (2 points) 10–20 mg/dL (1 point) Normal (0 points)
Mutation analysis Disease causing mutations on both 
chromosomes (4 points)
Disease causing mutations on 
one chromosome (1 point)
No mutation de-
tected (0 points)
Evaluation based on total WD diagnosis score:
≥ 4 points: diagnosis of WD highly likely
2–3 points: diagnosis of WD probable, more 
investigations needed
0–1 points: diagnosis of WD unlikely
MRI — magnetic resonance imaging; ULN — upper limit of normal; WD — Wilson’s Disease
ualberta.ca): c.1924 G>G/C (p.D642H) in exon 6 (missense 
mutation) and c.3842 G>G/ (p.G1281D) in exon 18 (missense 
mutation) [5]. 
Due to the divergence between findings i.e. late occurring 
hepatic symptoms, absence of neurological signs, and no 
changes typical for WD despite age, lack of family history, 
normal daily urinary copper excretion, but low serum ce-
ruloplasmin and the presence of two pathogenic variants of 
ATP7B gene, a 64Cu radioactive copper incorporation test was 
performed. 
 This test measures the incorporation of radioactive intrave-
nous copper into ceruloplasmin and involves the assessment of 
blood radioactivity after 2 (the starting value), 24, and 48 hours 
[6]. In healthy people, radioactive copper accumulates in the 
liver after a few hours, forms ceruloplasmin and is released 
into the blood, with almost all radioactive copper found in 
the blood after 24–48 hours. Calculated 24 hour/2 hour 64Cu 
ratios and 48 hour/2 hour 64Cu ratios are typically at or around 
1 in healthy individuals. In WD cases, copper accumulates 
in the liver more slowly and only partially incorporates into 
ceruloplasmin; most radioactivity stays in liver cells and much 
less radioactivity can be measured in blood. 
 In WD patients, 24 hour/2 hour and 48 hour/2 hour 
64Cu ratios are generally ≤ 0.36 and ≤ 0.4, respectively 
[6]. This test reflects the functional activity of the copper 
transporter ATP7B and is characterised by very high sen-
sitivity (48 hour/2hour 64Cu ratio – 98.6%) and specificity 
(48 hour/2hour 64Cu ratio – 100%). The test was performed on 
groups of patients who had genetically confirmed or excluded 
WD [6]. The limitations of this test are restrictions in copper 
isotope use in laboratories, so currently it is performed rarely 
for diagnostic needs. Radioactive copper test is regarded as 
a useful tool in experimental works where the aim is to restore 
function of mutated gene and potentially could be used in 
human gene therapy studies [7, 8].
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 In our patient, the incorporation of radioactive copper was 
similar to that seen in healthy people (24 hour/2 hour: 1.61 and 
48 hour/2 hour: 1.51), indicating that incorporation of 64Cu 
into apoceruloplasmin was preserved and that a diagnosis of 
WD could be excluded. 
 However, it raised the question as to why, despite having 
two disease-causing variants of gene, was the patient not 
suffering from WD? 
We suspect that two mutations confirmed as pathogenic, in 
our case, were present on one allele (uniparental isodisomy), 
which is rare but has been previously observed [9]. In our 
recent study of 248 patients with WD, we found three cases 
with three mutations [10]. As WD is an autosomal recessive 
disease, pathogenic mutations must be present on two alleles 
[2]. Unfortunately, we were unable to perform DNA analysis 
to check if one of this case’s parents also had two mutations.
Additionally, the low level of ceruloplasmin observed in 
our patient is a frequent ‘false positive’ test for WD, especially 
in the case of malabsorption, and should be taken into account 
carefully in such cases [1]. We suspect that the low ceruloplas-
min and copper serum levels were the result of malabsorption 
and general cachexia. The liver injury could be explained as 
a common extraintestinal manifestation of coeliac disease and 
ulcerative colitis and as the adverse effect of mesalazine treat-
ment [11, 12]. She had normal daily urinary copper excretion, 
which is a very sensitive test for WD. Her clinical course was 
not typical of WD, with neither K-F rings nor neurological 
symptoms, despite her age. 
The patient died two months after discharge from our 
department in another hospital. A post mortem was not per-
formed, so the diagnosis of liver disease remains uncertain. 
Using our case as an example, we would like to emphasise that 
the final diagnosis of WD cannot be guided solely by the results of 
genetic tests. Based on our experience as a reference WD centre, 
we strongly recommend that the diagnosis of WD must always 
be confirmed by clinical, laboratory and genetic compatibility.
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